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Abstract
Background: Maternal outcomes in most countries of the developed world are good. However, in many
developing/resource-poor countries, maternal outcomes are bleaker: Every year, more than 500,000 women die in
childbirth, mostly in resource-poor countries. Those who survive often suffer from severe and long-term
morbidities. One of the most devastating injuries is obstetric fistula, occurring most often in south Asia and sub-
Saharan Africa. Fistula treatment and care are available in many countries across Africa and Asia, but there is a lack
of reliable data around clinical factors associated with the success of fistula repair surgery. Most published research
has been retrospective. While these studies have provided useful information about the care and treatment of
fistula, they are limited by the design. This study was designed to identify practices in care that could lead to the
design of prospective and randomized controlled trials.
Methods: Self-administered questionnaires were completed by 40 surgeons known to provide fistula treatment
services in Africa and Asia at private and government hospitals. The questionnaire was divided into three parts to
address the following issues: prophylactic use of antibiotics before, during, and after fistula surgery; urethral
catheter management; and management practices for patients with urinary incontinence following fistula repair.
Results: The results provide a glimpse into current practices in fistula treatment and care across a wide swath of
geographic, economic, and organizational considerations. There is consensus in treatment in some areas (routine
use of prophylactic antibiotics, limited bed rest until the catheter is removed, nonsurgical treatment for
postsurgical incontinence), while there are wide variations in practice in other areas (duration of catheter use,
surgical treatments for postsurgical incontinence). These findings are based on a small sample and do not allow for
recommending changes in clinical care, but they point to issues for possible clinical trial research that would
contribute to more efficient and effective fistula care.
Conclusions: The findings from the survey allowed us to consider clinical practices most influential in the cost,
efficacy, and safety of fistula treatment. These considerations led us to formulate recommendations for eight
randomized controlled trials on the following subjects: 1) Efficacy/safety of short-term catheterization; 2) efficacy of
surgical and nonsurgical therapies for urinary incontinence; 3) technical measures during fistula repair to reduce
the incidence of post-surgery incontinence; 4) identification of predictive factors for “incurable fistula"; 5) usefulness
of urodynamic studies in the management of urinary incontinence; 6) incidence and significance of multi-drug
resistant bacteria in the fistula population; 7) primary management of small, new fistulas by catheter drainage; and
8) antibiotic prophylaxis in fistula repair.
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Genital fistula is an abnormal passage or opening
between the genital tract and the urinary or intestinal
tract. It is one of the most devastating maternal morbid-
ities and is seen most often in Africa and Asia. There
are three primary types of gential fistula:
￿ Obstetric, caused from prolonged or obstructed
l a b o r .T h i si st h em o s tc o m m o nc a u s eo fg e n i t a lf i s -
tula. During labor, the constant pressure of the baby’s
head against the vaginal and bladder or intestinal wall
tissue leads to necrosis, which causes a fistula to
develop. The fistula results in the uncontrolled passage
of urine and/or feces into the vagina.
￿ Iatrogenic which results from tearing of the vaginal
tissues, as in damage during obstetric or gynecologic
surgery such as cesarean delivery or hysterectomy.
This cause occurs less frequently than prolonged or
obstructed labor.
￿ Violent sexual assault, including rape and forced
insertion of objects into a woman’s vagina. A fistula
resulting from sexual violence is one example of a
“traumatic gynaecologic fistula”.
Women suffering from fistula live with chronic urin-
ary and/or fecal incontinence, which often leads to
social isolation, divorce, abandonment, and even abuse.
Many women report feeling shame about their condition
and become estranged from friends and family.
Fistulas occur in places where use and access to obste-
tric care is limited. While there are no sound data on
the number of women living with fistula, the most com-
monly cited estimate is more than 2 million women liv-
ing with fistula, with approximately 50,000 to 100,000
cases occurring annually, mostly in Africa, Asia, and the
Arab world [1]. Further, the unmet need for fistula
repair is estimated to be as high as 99% [2].
Throughout sub-Saharan Africa and parts of Asia, sur-
geons are working to treat fistula and its sequelae.
N e v e r t h e l e s s ,r e l i a b l ed a t aa b o u tt h ec l i n i c a lf a c t o r s
associated with the success of fistula repair surgery are
sorely lacking. Several attempts have been made to
develop classification systems for fistula, most of which
include a description of the site and size of the fistula.
There is no currently agreed upon international classifi-
cation system for fistula, and practitioners have issued a
call for an evidence-based approach to developing a sys-
tem. [3]. A few studies have been useful in identifying
factors that could lead to unsuccessful fistula closure
and continued incontinence, such as fistula location, fis-
tula size, and scarring and circumferential fistula [4,5].
O n es t u d yf o u n dt h a tw o m e na r em o r el i k e l yt o
develop urinary incontinence after obstetric fistula repair
if any of the following are present [6].
￿ Involvement of the urethra
￿ Small functional bladder capacity
￿ Large diameter of fistula
￿ Need for vaginal reconstruction
In an uncontrolled observational study, 55% of women
reported persistent urinary incontinence after surgery,
while 38% reported altered fecal continence [7].
Another retrospective study reviewed the outcome of
fistula repair surgery following three different durations of
catheterization: 10 days, 12 days, and 14 days. (These
patients’ fistulas were classified by the Goh system [8].)
The authors found that patients with more damage (e.g.,
more vaginal scarring, a larger fistula, and greater urethral
damage) were assigned to a longer catheterization period
by the operating surgeon. The researchers concluded that
shorter periods of catheterization may be adequate for
patients with less complicated fistula, but they note that
randomized clinical trials are needed to assess the effec-
tiveness of shorter durations of catheterization [5].
O n es t u d ys h o w e dt h er e s u l t so fas u r g e o nw h o
employed catheterization for possible spontaneous heal-
ing and surgical repair in less than three months from
the formation of the fistula [9]. The author found that
15% of patients healed spontaneously with the catheter,
with 96% of those women remaining continent. The rest
of the women underwent fistula repair as soon as the
fistula edge was clean (even with inflammation), with an
87% success rate (success defined as continence).
While these studies provide useful information, most
of the data were gathered from retrospective record
reviews and are therefore limited by the nature of the
design: Only information that is available in the record
can be analyzed.
At a 2005 international meeting [10], clinicians and
public health professionals identified three treatment
and care areas that needed more attention:
￿ The use of prophylactic antibiotics
￿ Catheter management after fistula repair
￿ The need for women who have had a fistula to
have a cesarean delivery for subsequent pregnancies
The group also identified six research needs
1. Assessing the burden of disease attributable to
fistula
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such as delaying early childbearing and raising
awareness about the need for skilled attendance at
birth
3. Developing a standard classification system
4. Identifying evidenced-based practices for success-
ful management of fistula
5. Assessing low-cost treatment methods for
resource-poor settings
6. Identifying barriers to emergency obstetric care at
the community, facility, provider, and patient levels
While these research topics are important, the field
also needs prospective and randomized controlled trial
studies that can help identify best practices for fistula
surgery.
Fistula Care, a five-year project (2007-2012) funded by
the U. S. Agency for International Development
(USAID) and its partners are interested in identifying
treatment regimens that could contribute to influencing
policies and practices and that could lead to improved
care for women living with fistula. In 2008, through a
consultative process, fistula clinicians from 10 countries
identified three priority areas that could be appropriate
for clinical trials [11]:
￿ Use of prophylactic antibiotics
￿ The role of catheterization in fistula care
management
￿ Management of urinary incontinence following fis-
tula surgery
Before embarking on any clinical trials, Fistula Care
decided to conduct a descriptive clinical review of cur-
rent practices around these three issues. The goal was
to identify current practices in order to frame research
questions for one or more clinical trial.
Methods
Study Population
T h es t u d yu s e dap u r p o s i v es a m p l eo fs u r g e o n sw h o
perform fistula surgery in sub-Saharan Africa and South
Asia. The authors compiled a list of 82 known surgeons
working on fistula in 21 countries in sub-Saharan Africa
and one country in South Asia; 12 of these surgeons
(15%) reside outside of Africa and Asia and periodically
serve as visiting surgeons in countries in these regions.
Potential respondents included:
￿ Surgeons working at government and private hos-
pitals, several of which are supported by interna-
tional nongovernmental organisations (e.g.,
EngenderHealth/Fistula Care project, United Nations
Population Fund [UNFPA])
￿ Contacts from two professional societies–the Inter-
national Society of Obstetric Fistula Surgeons
(ISOFS) and the Pan African Urologic Surgeons
Association (PAUSA)
The study used no other selection criteria, such as size
of hospitals where respondents work, funding, locations,
or level of activity. The study proposal was reviewed
and approved using EngenderHealth’s standard operat-
ing procedures for ethical and technical quality in
research. IRB approval was not required for the study as
it did not involve any clinical procedures or use of
patient records.
Study Design
The authors were able to locate e-mail addresses for a
total of 66 fistula surgeons (80%) from among the
potential respondents. Letters of invitation were sent by
e-mail to 62 of these surgeons. Four invitation letters
were sent by messenger from Abuja, Nigeria, to fistula
surgeons in Northern Nigeria who lacked e-mail access.
The letter explained the rationale and design of the
study– to explore knowledge gaps regarding care for
women living with fistula by gathering information
about current practices in order to formulate future
research questions–and included an invitation to partici-
pate. Surgeons who expressed interest received the
questionnaire by e-mail and were asked to complete and
return it. The questionnaire was divided into three
parts, to cover each clinical area of interest. Participants
were assured that all information they provided would
be considered confidential. Respondents received an
informed consent form for participation in the study.
Participants received all study documents (letter of invi-
tation, instructions, consent, and questionnaires) in
either English or French.
Data Analysis
T h ed a t af r o mt h i ss t u d ya r ep u r e l yd e s c r i p t i v e( f r e -
quencies and ranges) and not amenable to formal statis-
tical analysis. Rather, they are used as a general guide to
current practices in the areas of clinical care in question,
as described above. The data were reviewed for broad
trends that frame current practices.
Results
Of the 66 surgeons invited to participate in the study, 51
replied to our invitation (77%); 49 agreed to participate
and were sent a questionnaire. Two invitees responded
but declined to participate.
Among the 49 who agreed to participate, a total of 40
returned a completed questionnaire, yielding a final
response rate of 61% (40/66). The high response rate
was partly due to the authors’ s e n d i n gr e m i n d e re - m a i l s
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not know why we did not hear from 26 of the surgeons
we contacted. The authors believe that surgeons
responded to our survey for two reasons: 1) they are
interested in contributing to the learning required for
more evidence-based research to improve fistula services
and 2) they would be interested in participating in
future research. Seven of the 40 respondents are cur-
rently participating in a prospective study on fistula out-
comes sponsored by EngenderHealth.
Respondents included surgeons who provide fistula
care services in Asia, East Africa, Central/Southern
Africa, and West Africa (Table 1). Respondents provide
fistula care in a range of health care facilities, from free-
standing fistula facilities to general hospitals, some
under governmental and others under nongovernment
organizational management.
The majority of respondents (32) were country
nationals, while one-fifth were international surgeons
(Table 1). (Three of the eight international respondents
resided in Asia or Africa; the remainder travelled peri-
odically to provide services.) The majority of respon-
dents (36) were male. Just over half of the respondents
perform surgery at sites supported by the Fistula Care
project.
The surgeons reported that they perform from 20 to
700 fistula repair cases per year, with a mean of 168 and
median of 150 cases.
Antibiotic Usage
Resources for Use of Antibiotics
The study found that antibiotics are usually available to
fistula surgeons. Just over two-thirds said they use their
hospital pharmacy formulary. Only a few reported that
their patients must acquire antibiotics through private
pharmacies. Several respondents commented that their
supply of antibiotics comes via the organization spon-
soring the fistula surgery. Over three-quarters of respon-
dents reported they have access to quinolones and to
aminoglycosides, and more than half have third-genera-
tion cephalosporins (see Table 2). Only two respondents
reported access to extended spectrum (“rescue”)
antibiotics like imipenem for use in a setting of bacterial
multi-drug resistance. Factors affecting the availability of
antibiotics include market-driven factors (drug availabil-
ity and hospital budget), hospital formulary, or govern-
ment essential drug lists.
Table 1 Respondents
N%
No. of possible surgeons to contact 82
No. of letters of invitation sent 66 80%
No. of surgeons who agreed to participate in the study 49 74%
No. who returned completed questionnaires 40 82%
Primary region where respondents provide fistula care
Asia 5 13%
West Africa 21 53%
Central/Southern Africa 4 10%
East Africa 10 25%
Nationality
Country-national surgeon 32 80%
International surgeon 8 20%
No. of respondents working at Fistula Care-supported
sites
18 45%
Respondents’ primary language
French 18 45%
English 22 55%
Table 2 Antibiotic Practices for Fistula Surgery
N%
Antibiotics usually available for pelvic surgery *
Aminoglycosides (e.g., gentamicin/tobramycin) 31 78%
Quinolones (e.g., ciprofloxacin) 31 78%
Second-generation cephalosporins (e.g., cefuroxime) 15 38%
Third-generation cephalosporins (e.g., ceftriaxone) 22 55%
“Rescue” antibiotics for multi-resistant organisms (e.g.,
imipenem)
25 %
Factors influencing availability of antibiotics^
Market factors: drug availability and hospital budget 12 30%
Hospital formulary set by administration 11 28%
Ministry of Health’s essential drug list 8 20%
Donation from partners 4 10%
Other 4 10%
No response 1 3%
Use of prophylactic antibiotics^
For every fistula case 23 58%
For selected fistula cases 14 35%
Never 2 5%
No response 1 3%
Most important factor in choice of prophylactic
antibiotics^
Recommendations of medical literature 9 23%
Surgeon training in vesicovaginal fistula surgery 9 23%
Availability 7 18%
Personal choice 5 13%
Cost 2 5%
Does not use prophylactic antibiotics 1 3%
Other 7 18%
* Multiple responses allowed; percentages exceed 100%.
^ Exceeds 100% due to rounding.
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Clinicians debate the definition of antibiotic prophylaxis;
for the purposes of this study the term means a single
dose of antibiotics given before surgery to prevent the
development of infection.
When asked about antibiotic use as prophylaxis, more
than half reported using antibiotics on every surgical
case, and only two respondents reported that they do
not use antibiotics routinely in fistula care (Table 2).
However, some internal inconsistency was noted in the
responses. The questionnaire included the response
choice “Id o n ’t use prophylactic antibiotics” for five dif-
ferent questions, and the number of respondents who
reported non-use of antibiotics ranged from zero to five.
Overall, the majority of respondents reported that
their patients receive prophylactic antibiotics. However,
there was little agreement as to what type of antibiotic
and regimen to use. The most commonly chosen single
agent was an aminoglycoside (e.g., gentamicin). Nearly
three-quarters of the respondents reported that they
start patients on antibiotics before surgery. The duration
of antibiotic use for “prophylaxis” varied widely (see Fig-
ure 1): 12 respondents report they give a single preo-
perative dose, and 18 respondents continue antibiotics
more than 24 hours after surgery. (By clinical definition,
continuation of antibiotics beyond 24 hours is consid-
ered empiric antibiotic therapy, not prophylaxis.) About
half of the surgeons (18) reported having a routine anti-
biotic choice for all fistula patients; most of the remain-
ing respondents (16) stated that the choice of antibiotic
was made on an individual basis with each case.
Rationale for Use of Prophylactic Antibiotics
Many respondents said that their routine use of antibio-
tics is based on either the medical literature or their
clinical training in fistula surgery (Table 2). But “perso-
nal experience” and “availability” were also common
reasons given, often by both those who do not use pro-
phylactic antibiotics and those who do. Cost to the
patient was not a significant factor in decision making.
Urethral Catheter Management
Resources for Use of Urethral Catheter
Almost two-thirds of respondents reported that their
hospitals purchase catheters locally. One-third receive
catheters from donors; only four respondents reported
requiring patients to purchase catheters before surgery.
Approximately three-quarters of respondents said that
their choice of catheter is not affected by availability.
Current Practices in Catheter Management
Catheter management practices varied widely among
respondents (Table 3). Some surgeons stated that they
prefer big catheters (20F as a routine choice), while
others prefer small 12F catheters. The average preferred
size was a 16-18F tube, with nearly all preferring the
standard Foley catheter. Almost half preferred latex
catheters; one-third said that the composition of the
catheter does not matter.
Nearly one-third of respondents reported open drai-
nage of the catheter into a basin (Table 3); nearly all
respondents reported that they use a catheter with a bal-
loon. Only one-fifth of the surgeons reported they
require bed rest until the catheter is removed; two-
thirds never make patients stay in bed until the catheter
is removed (Table 3).
Duration of catheter use showed the greatest range of
practice. Respondents were asked “How long are cathe-
ters left in place after fistula repair?” for three types of
fistula–simple, large, and difficult. (Because there is no
standard terminology for the description of fistula
the terms “simple,”“ large,” and, “difficult” were left to
the respondents to interpret.) For a “simple” fistula, the
average was 12 days, ranging from a minimum of five
days to 21 days (see Figure 2). For a “difficult” fistula,
respondents reported leaving the catheter indwelling for
as many as 42 days as a routine (the average was 21).
For a “large” fistula the time was intermediate, with a
range of 10-30 days and an average of 17. About one-
quarter of surgeons routinely performed a dye test
before removing the catheter.
Respondents were asked about their practice in blad-
der “training": intermittent clamping of the catheter to
allow the bladder to fill and distend to some degree
before catheter removal. (The precise definition of this
term was not clear in the questionnaire and was left to
the interpretation of the respondent.) Less than half of
the respondents reported that they occasionally begin
clamping the catheter before removal to begin bladder
training (Table 3). After the catheter is removed, about
three-quarters perform bladder training of some sort for
at least a part of their patient population (Table 3).
Figure 1 Length of Prophylactic Antibiotic Use.D e s c r i p t i o n :
length of prophylactic use reported by respondents. Y axis: Number
of respondents. X axis, Period of use (one dose, for 24 hours, More
than 24 hours, other comments).
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ter is removed, more than half of surgeons said that
they instruct the patients in intermittent self-catheteriza-
tion (Table 3). When a patient requires prolonged
catheterization, about one-fifth of respondents said that
they discharge a patient to go home with the catheter
still indwelling.
Catheter Management by Nursing Staff
Most respondents reported that nursing staff in their
facilities flush catheters; just over one-third reported
that nurses replace the catheter if it becomes blocked,
without the need for specific direction from the
physician.
Catheterization as Primary Treatment of Select Fistula
A small number of women present with small, “fresh”,
and/or simple fistula that can be treated with catheter
drainage alone. (Within the fistula community, the term
“fresh” is understood to refer to a fistula occurring within
the last 3-6 months.) One provider reported managing
nearly one-third of cases in this way, while others reported
Table 3 Role of Catheterization
Ideal choice of catheter size (French) for routine urinary fistula repair
Minimum 12
Maximum 20
Average 17
No response 6
N%
Ideal choice of catheter type^
Standard Foley catheter 37 93%
Straight catheter without balloon 13 %
Specialty catheter 13 %
No response 13 %
Routine catheter drainage
Closed drainage (catheter attached to closed drainage bag) 26 65%
Open drainage (catheter drains into basin, bottle, or bucket) 12 30%
No response 25 %
Patients remain on bed rest until the catheter is removed^
Always 7 18%
Sometimes 6 15%
Never 23 58%
No response 4 10%
Bladder training/clamping the catheter carried out before the catheter is removed^
Always 5 13%
Sometimes 11 28%
Never 23 58%
No response 13 %
After the catheter is removed, a program of bladder training begins
Always 6 15%
Sometimes 22 55%
Never 10 25%
No response 25 %
Patients who are unable to urinate are taught intermittent self-catheterization ^
Yes 15 38%
Sometimes 9 23%
No 15 38%
No response 13 %
^ Exceeds 100% due to rounding.
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this approach. Many respondents agreed that primary
treatment of fistula with a catheter can be a successful
therapy in select women, but that the ideal patient for this
treatment is simply not seen often enough.
Management of Urinary Incontinence after Fistula Repair
Resources for Diagnosis of Urinary Incontinence
The majority of respondents said that they diagnose
post-surgery urinary incontinence on simple clinical
grounds: About three-quarters use a combination of his-
tory, a physical examination, and a negative dye test,
while one-fifth use a physical examination and history.
Only a few of the respondents reported ever using uro-
dynamic studies (UDSs) (see Table 4). Study respon-
dents were asked to self-report a rough estimate of the
incidence of incontinence in their patients after success-
ful closure of an obstetric fistula. These estimates ran-
ged from as low as 0.5% to as high as 30%, and overall,
these self-estimates averaged 11%.
Importance of Post-Surgery Incontinence
Three-quarters of surgeons believe that post-surgery
incontinence is important because the condition is com-
mon and it seriously affects the woman’sq u a l i t yo fl i f e .
Consequently, respondents routinely include it in the
counseling provided to patients before repair surgery.
Intra-Operative Predictive Factors for Post-Surgery
Incontinence
Respondents ranked a list of physical examination find-
ings in order of relevance (1 through 8) as predictors of
u r i n a r yi n c o n t i n e n c ea f t e rf i s t u l ar e p a i r .T h r e ef a c t o r s –
urethral length, degree of urethral damage, and presence
of pelvic prolapse–were the surgeons’ top three choices.
Pelvic prolapse was considered the least important of
these three. About one-fifth of the respondents said they
would consider not performing fistula repair if they
believed the patient was likely to have severe inconti-
nence after surgery.
Intra-Operative Techniques for Preventing Post-Surgery
Incontinence
According to most respondents, certain technical inter-
ventions done during the fistula repair itself can reduce
the risk of post-surgery incontinence. Most popular
among these procedures was lengthening of the urethra,
followed by techniques classically used in wealthy
nations to treat stress incontinence such as slings and
bladder neck suspensions (Table 4).
Current Practices in Nonsurgical and Surgical Treatment
Respondents reported use of nonsurgical treatments for
post-repair incontinence (Table 4). Just over three-quar-
ters of respondents recommend pelvic floor exercises,
just over half prescribe medications, and less than half
institute bladder training. Few had tried injection of
periurethral bulking agents or use of urethral plugs.
Surgical Treatments Following Repair
Two-thirds of surgeons said that they had received for-
mal training in surgical therapy for urinary incontinence.
The most popular individual surgical procedure was the
pubovaginal sling and bladder neck suspension, per-
formed by about half of the respondents (Table 4). A few
respondents reported using tension-free vaginal tape,
which involves insertion of a loose sling of plastic mesh.
Definition and Management of Treatment “Failure”
The questionnaire asked respondents how they define
success of fistula treatment surgery. One-quarter define
surgical success anatomically, while the majority favor a
functional definition of success, meaning that the patient
needs to be dry after surgery for the intervention to be
considered successful.
On average every year, each surgeon sees about 13
women (range 0-50) with post-surgery incontinence for
whom the initial intervention, either surgical or nonsurgical,
Figure 2 Duration of Catheter Use by Type of Fistula. Description: duration of catheter use by type of fistula reported by respondents. Y axis:
Number of Days Post Surgical Catheterization (minimum/maximum). X Axis: Type of fistula: Simple fistula, Large fistula, Difficult fistula.
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options. Nonoperative treatments were common: The
majority offer counseling, about half offer training in long-
term pelvic floor exercises, and a few provide urethral plugs
(Table 4). Less than half said that they offer urinary diver-
sion as a treatment option for women failing all other inter-
vention. About half said that they were not trained in
diversion procedures.
Discussion
Study Limitations
The study was an attempt to describe in broad strokes
current practices in three defined dimensions of fistula
care. The sample size and sampling method did not
allow for analysis beyond descriptive statistics. Because
the community of fistula surgeons is small, the research-
ers could not randomly select a subgroup of respon-
dents. Because the questionnaire used multiple choice
and pre-coded responses, the study was not able to cap-
ture all aspects of clinical practice. While most ques-
tions included an “other category” where respondents
could provide other responses, this feature was not used
by all respondents. A further limitation of the design is
that self-reporting may reflect ideal rather than actual
practice. While the findings do not allow the authors to
recommend changes in clinical care, the research is
Table 4 Management of Urinary Incontinence after Fistula Repair
N%
Method for diagnosing incontinence after fistula surgery^
By history and physical examination, including dye test 29 73%
By history and physical examination, without dye test 8 20%
By urodynamic studies 13 %
No response 25 %
Operative procedures performed to reduce the risk of postoperative SUI*
Urethral lengthening 17 43%
Bulbocavernosus sling (Browning) 14 35%
Bladder neck suspension 11 28%
Medial thigh fascio-cutaneous flaps 38 %
Other 11 28%
No response 13 %
Non-surgical treatment provided for incontinence after fistula repair*
Pelvic floor exercises 30 75%
Anticholinergic medications (buscopan, oxybutinin, etc.) 21 53%
Bladder training 17 43%
Urethral plugs 5 13%
Peri-urethral injection (autologous fat, collagen, microspheres) 2 5%
Other 5 13%
No response 38 %
Surgical treatments provided for urinary incontinence after surgery*
Pubovaginal sling surgery 19 48%
Bladder neck suspension 18 45%
Vaginal tape procedure 6 15%
Other 10 25%
No response 25 %
Treatments/care provided to patients who have failed surgical treatment for stress incontinence*
Counseling 28 70%
Long-term pelvic floor exercises 22 55%
Urinary diversion 14 35%
Urethral plugs 7 18%
Other/comment 38 %
* Multiple responses allowed; percentages exceed 100%.
^ Exceeds 100% due to rounding.
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study on current clinical practice in fistula care. This
research provides guidance about future strategies for
research and fistula care.
Current Practices
Antibiotic Use
Antibiotic therapy is expensive and 95% of the study
respondents use antibiotic prophylaxis; thus, this area is
f e r t i l eg r o u n df o rs t u d y( T a b l e1 ) .I ti sd i f f i c u l tt od i s -
cern from the data any patterns in the choice of antibio-
tics or duration of therapy. Two-thirds of respondents
reported use of empiric, rather than prophylactic, anti-
biotic therapy. Certainly, as training curricula for fistula
surgeons are being developed, guidance for antibiotic
use needs to be standardized. One of the few clinical
trials in the literature regarding peri-operative care in
the fistula patient specifically addressed antibiotic use in
the fistula population [12]. This study, from Benin,
found no benefit from prophylactic antibiotics. If this is
true, antibiotic use may be wasting significant resources.
Adaptation of guidelines from Western nations is a
potential approach. Major professional organizations
with expertise in pelvic surgery, such as the American
College of Obstetricians and Gynecologists [13] and the
American Urological Association [14] have well-defined
policies regarding antibiotic use. Furthermore, research
has examined the use of antibiotics with “contaminated”
wounds and other types of pelvic surgery; thus, there is
probably little to be gained from studies specifically
focused on fistula repair. Are separate clinical trials for
fistula repair necessary if large studies have already been
performed for other types of pelvic surgery? The authors
believe that a large, complex, and expensive trial is not
needed.
In this study, a few surgeons reported having access to
expensive extended spectrum antibiotics to treat infec-
tion caused by multi-drug resistant organisms. In recent
fistula care outreach camps in West Africa, the preva-
lence of multi-drug resistance has been alarmingly high
[15,16 ]. If fistula care centers do not have the antibio-
tics to treat these infections, patients are at high risk for
death from sepsis. The fistula care community may need
to re-evaluate the provision of antibiotic support. A clin-
ical trial could perform urine culture at admission in a
broad range of centers; such research would help deter-
mine the prevalence and risk of multi-drug resistance.
Urinary Incontinence after Fistula Repair
This is clearly another area where more research is
needed. The survey found that surgeons do not com-
monly use UDSs to manage incontinence after fistula
repair. Research could determine if UDSs are helpful in
diagnosing fistula, identifying appropriate therapies, and
improving outcomes. However, urodynamics hardware
and consumables are expensive, and training staff to
perform these complex tests would be time-consuming
and costly.
According to one study, presented at the International
Society of Obstetric Fistula Surgeons 2
nd Annual Meet-
ing in Nairobi (2009), approximately one-third of
women have significantly impaired bladder emptying
after fistula repair (Williams G: Diagnosis and manage-
ment of incontinence after fistula surgery at Addis
Ababa Fistula Hospital, unpublished). In this study sur-
geons reported using a wide range of treatments for
urinary incontinence after fistula repair. Both the non-
surgical and surgical therapies identified in this study
were developed for a completely different condition–
namely, stress urinary incontinence (SUI) from loss of
pelvic floor support after childbirth. Clinicians do not
know if any of these treatments, invasive or otherwise,
are of benefit for incontinence following fistula repair. A
prospective clinical trial would enrol women with urin-
ary incontinence after fistula repair and then tabulate
the results for the various therapies used. In such a trial,
a large number of patients would be necessary to case-
match for their injuries before they are randomized to
different treatment modalities. If clear differences in
outcomes emerge, then the more efficacious interven-
tions can be recommended to the community of fistula
surgeons. Such a study might lead to other trials to
refine the field’s understanding of urinary incontinence
after repair surgery. Researchers could also assess the
effectiveness of treatments in combination to see if out-
comes improve.
Many respondents agreed that the way in which
repairs is done affects the risk of incontinence after sur-
gery. But clinicians do not know which types of repair
are most effective. Only a clinical trial will answer this
question.
The study included questions about urinary diversion
in patients with untreatable incontinence after fistula
repair. Delineating the exact profile of such an incurable
condition is an attractive possibility for a clinical trial.
Such cases are relatively few, however. Thus it would be
time-consuming and costly to recruit enough patients to
establish statistical significance.
Catheter Management
Duration of catheter use after repair is the single most
important issue in terms of possible impact. For most
facilities, length of stay is determined by duration of
catheter drainage. Length of stay may be the primary
determinant of surgical cost and of capacity for care.
Shorter stays mean more rapid turnover and, in turn,
more women receiving the opportunity for care. If
everyone were leaving catheters in place for 21 days, it
would be difficult to argue that perhaps this length of
time could be reduced. However, the survey showed
Arrowsmith et al. BMC Pregnancy and Childbirth 2010, 10:73
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42 days. If the five-day patients do as well as the 42-day
patients, the implications are enormous. If duration of
catheterization were shortened, capacity would instantly
increase without any capital investment. A clinical trial
to address this issue is much needed.
Conclusions
The primary objective of this study was to identify
issues in fistula care which would benefit from clinical
trials. In order to be the subject of a clinical trial, a
practice needs to be pervasive and have significant
implications in terms of costs, time, efficiency, or out-
come. This survey provides a snapshot of current fistula
practice across a wide swath of geographic, economic,
and organizational conditions. The results point out sur-
prising degrees of consensus in some areas, while high-
lighting the tremendous disparity of practices in other
areas.
Based on the findings from this study and on discus-
sions at two international meetings on fistula care
[10,11], the authors have identified eight possible topics
for clinical study: These topics, in order of priority, are:
1. Efficacy/safety of short-term catheterization after
fistula repair
2. Efficacy of surgical and nonsurgical therapies for
urinary incontinence after fistula repair
3. Technical measures during fistula repair to reduce
the incidence of post-surgery incontinence
4. Identification of predictive factors for the “incur-
able fistula”
5. Usefulness of UDSs in management of urinary
incontinence after fistula repair
6. Incidence and significance of multi-drug resistant
bacteria in the fistula population
7. Primary management of small, new fistulas by
catheter drainage
8. Antibiotic prophylaxis in fistula repair (choice of
agent, onset and duration of therapy)
In addition, the authors encourage the fistula care
community to do the following:
1. Emphasize training in the use of antibiotics (what
is prophylactic antibiotic use, what is empiric ther-
apy), the problem of multi-drug resistant organisms,
and the need for “rescue” antibiotic therapy.
2. Produce a technical guidance document based on
a literature review that could be used to support this
training. Draw upon policies set by major medical
organizations when preparing this document.
Include information that antibiotic therapy may not
be beneficial.
Next Steps
EngenderHealth, the implementing agency for Fistula Care,
is seeking funding to conduct a clinical trial on short-term
catheterization, the most important priority identified in
this paper. The organization will form an advisory group
composed of clinical experts in fistula treatment, including
principal investigators from potential study sites, to jointly
design a clinical protocol for the study.
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